Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Valeant Can Meet Mandatory Payment Deadlines, Exec Insists

This article was originally published in Scrip

Executive Summary

Buying back shares and debt is where Valeant Pharmaceuticals International Inc. sees return on investment in the short-term, the Jefferies 2015 Global Healthcare Conference in London heard on Nov. 18. Apparently there isn't enough cash available for large scale M&A but there will continue to be smaller "tuck in" deals, according to Laurie Little, senior vp of investor relations.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register